vericiguat (Verquvo) Report issue

Small molecule Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N
  • InChIKey: QZFHIXARHDBPBY-UHFFFAOYSA-N
  • Mol. Mass: 426.39
  • ALogP: 2.56
  • ChEMBL Molecule:
    vericiguat  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$14.1079 - $14.3838
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bay 1021189 | vericiguat

Organizations (13)

Research & Development (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Heart Failure (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Brain Diseases (Phase 4)

Breast Neoplasms (Phase 2)

Child (Phase 1)

Coronary Artery Disease (Phase 1)

Coronary Disease (Phase 2)

Endothelial Cells (Phase 4)

Heart Diseases (Phase 2)

Heart Failure (Phase 4)

Hypertrophy, Left Ventricular (Phase 2/Phase 3)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Metabolic Syndrome (Phase 2)

Pharmacokinetics (Phase 1)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 13

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue